<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MEQUITAZINE" rxcui="29528">
<ATC code="R06AD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzymatic inhibitor</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METOPROLOL" rxcui="6918">
<ATC code="C07AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the fluoxetine. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring, if needed, adjustment of the dosage of themetoprolol during the length of the treatment with the fluoxetine and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEBIVOLOL" rxcui="31555">
<ATC code="C07AB12" />
<ATC code="C07BB12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the nebivolol, especially with excessive bradycardia, due to inhibition of its metabolism by the antidepressant </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name=" FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with the fluoxetine and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RISPERIDONE" rxcui="35636">
<ATC code="N05AX08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of its undesirable effects</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine. </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>237-FLUOXETINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLUOXETINE" rxcui="4493">
<ATC code="N06AB03" />
<ATC code="N06CA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with fluoxetine and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
